Peptide exchange in MHC molecules

Immunological Reviews

Volumn 172, Issue , 1999, Pages 229-238

  Jensen, Peter E ^a   Weber, Dominique A ^a   Thayer, Wesley P ^a   Westerman, Larry E ^a   Dao, Chinh T ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; HLA D ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BINDING SITE; ENDOPLASMIC RETICULUM; ENDOSOME; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PH; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0033428765     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01368.x     Document Type: Review

References (102)

1. 1. Jensen PE. Peptide binding and antigen presentation by class II histocompatibility glycoproteins. Biopolymers 1997;43:303-322.
2. 2. Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 1998;16:323-358.
3. 3. Garrett TPJ, Saper MA, Bjorkman PJ, Strominger JL, Wiley DC. Specificity pockets for the side chains of peptide antigens in HLA-Aw68. Nature 1989;342:692-696.
4. 4. Stern LJ, Wiley DC. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell 1992;68:465-477.
5. 5. Fahnestock ML, Tamir I, Narhi L, Bjorkman PJ. Thermal stability comparison of purified empty and peptide-filled forms of a class I MHC molecule. Science 1992;258:1658-1662.
6. 6. Brown JH, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993;364:33-39.
7. 7. Stern LJ, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994;368:215-221.
8. 8. Madden DR, Gorga JC, Strominger JL, Wiley DC. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature 1991;353:321-325.
9. 9. Lanzavecchia A, Reid PA, Watts C. Irreversible association of peptides with class II MHC molecules in living cells. Nature 1992;357:249-252.
10. 10. Nelson CA, Petzold SJ, Unanue ER. Peptides determine the lifespan of MHC class II molecules in the antigen-presenting cell. Nature 1994;371:250-252.
11. 11. Zhong G, Castellino F, Romagnoli P, Germain RN. Evidence that binding site occupancy is necessary and sufficient for effective major histocompatibility complex (MHC) class II transport through the secretory pathway redefines the primary function of class II-associated invariant chain peptides (CLIP). J Exp Med 1996;184:2061-2066.
12. 12. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995;378:457-462.
13. 13. Ceman S, Sant AJ. The function of invariant chain in class II-restricted antigen presentation. Semin Immunol 1995;7:373-387.
14. 14. Roche PA, Cresswell P. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature 1990;345:615-618.
15. 15. Teyton L, et al. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. Nature 1990;348:39-44.
16. 16. Busch R, Cloutier I, Sekaly RP, Hämmerling GJ. Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO J 1996;15:418-428.
17. 17. Freisewinkel IM, Schenck K, Koch N. The segment of invariant chain that is critical for association with major histocompatibility complex class II molecules contains the sequence of a peptide eluted from class II polypeptides. Proc Natl Acad Sci USA 1993;90:9703-9706.
18. 18. Bijlmakers MJ, Benaroch P, Ploegh HL. Mapping functional regions in the lumenal domain of the class II-associated invariant chain. J Exp Med 1994;180:623-629.
19. 19. Romagnoli P, Germain RN. The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J Exp Med 1994;180:1107-1113.
20. 20. Sette A, Southwood S, Miller J, Appella E. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J Exp Med 1995;181:677-683.
21. 21. Liang MN, Beeson C, Mason K, McConnell HM. Kinetics of the reactions between the invariant chain (85-99) peptide and proteins of the murine class II MHC. Int Immunol 1995;7:1397-1404.
22. 12. Thayer WP, Ignatowicz L, Weber DA, Jensen PE. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules. J Immunol 1999;162:1502-1509.
23. 23. Kropshofer H, Vogt AB, Hämmerling GJ. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding. Proc Natl Acad Sci USA 1995;92:8313-8317.
24. 24. Kropshofer H, Vogt AB, Stern LJ, Hämmerling GJ. Self-release of CLIP in peptide loading of HLA-DR molecules. Science 1995;170:1357-1359.
25. 25. Stumptner P, Benaroch P. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region. EMBO J 1997;16:5807-5818.
26. 26. Siebenkotten IM, Carstens C, Koch N. Identification of a sequence that mediates promiscuous binding of invariant chain to MHC class II allotypes. J Immunol 1998;160:3355-3362.
27. 27. Blum JS, Cresswell P. Role for intracellular proteases in the processing and transport of class II HLA antigens. Proc Natl Acad Sci USA 1988;85:3975-3979.
28. 28. Riese RJ, et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996;4:357-366.
29. 29. Mellman I, Fuchs R, Helenius A. Acidification of the endocytic and exocytic pathways. Annu Rev Biochem 1986;55:663-700.
30. 30. Jensen PE. Regulation of antigen presentation by acidic pH. J Exp Med 1990;171:1779-1789.
31. 31. Jensen PE. Enhanced binding of peptide antigen to purified class II major histocompatibility glycoproteins at acidic pH. J Exp Med 1991;174:1111-1120.
32. 32. Jensen PE. Long-lived complexes between peptide and class II MHC are formed at low pH with no requirement for pH neutralization. J Exp Med 1992;176:793-798.
33. 33. Sherman MA, Runnels HA, Moore JC, Stern LJ, Jensen PE. Membrane interactions influence the peptide binding behavior of DR1. J Exp Med 1994;179:229-234.
34. 34. Mouritsen S, Hansen AS, Petersen BL, Buus S. pH dependence of the interaction between immunogenic peptides and MHC class II molecules. Evidence for an acidic intracellular compartment being the organelle of interaction. J Immunol 1992;148:1438-1444.
35. 35. Reay PA, Wettstein DA, Davis MM. pH dependence and exchange of high and low responder peptides binding to a class II MHC molecule. EMBO J 1992;11:2829-2839.
36. 36. Sette A, Southwood S, O'Sullivan D, Gaeta FCA, Sidney J, Grey HM. Effect of pH on MHC class II-peptide interactions. J Immunol 1992;148:844-851.
37. 37. Harding CV, Roof RW, Allen PM, Unanue ER. Effects of pH and polysaccharides on peptide binding to class II major histocompatibility complex molecules. Proc Natl Acad Sci USA 1991;88:2740-2744.
38. 38. Boniface JJ, Lyons DS, Wettstein DA, Allbritton NL, Davis MM. Evidence for a conformational change in a class II MHC molecule occurring in the same pH range that enhances antigen binding. J Exp Med 1996;183:119-126.
39. 39. Runnels HA, Moore JC, Jensen PE. A structural transition in class II MHC proteins at mildly acidic pH. J Exp Med 1996;183:127-136.
40. 40. Stryhn A, et al. pH dependence of MHC class I-restricted peptide presentation. J Immunol 1996;156:4191-4197.
41. 41. Sherman MA, Weber DA, Jensen PE. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity 1995;3:197-205.
42. 42. Sloan VS, et al. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 1995;375:802-806.
43. 43. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell 1995;82:155-165.
44. 44. Vogt AB, Kropshofer H, Moldenhauer G, Hämmerling GJ. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM. Proc Natl Acad Sci USA 1996;93:9724-9729.
45. 45. Fling SP, Arp B, Pious D. HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature 1994;368:554-558.
46. 46. Morris P, et al. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 1994;368:551-554.
47. 47. Cho SG, Attaya M, Monaco JJ. New class II-like genes in the murine MHC. Nature 1991;353:573-576.
48. 48. Kelly AP, Monaco JJ, Cho SG, Trowsdale J. A new human HLA class II-related locus, DM. Nature 1991;353:571-573.
49. 49. Mosyak L, Zaller DM, Wiley DC. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. Immunity 1998;9:377-383.
50. 50. Marks MS, Roche PA, van Donselaar E, Woodruff L, Peters PJ, Bonifacino JS. A lysosomal targeting signal in the cytoplasmic tail of the β chain directs HLA-DM to MHC class II compartments. J Cell Biol 1995;131:351-369.
51. 51. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 1992;360:474-477.
52. 52. Sette A, et al. Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. Science 1992;258:1801-1804.
53. 53. Weber DA, Evavold BD, Jensen PE. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 1996;274:618-620.
54. 54. Van Ham SM, Gruneberg U, Malcherek G, Broker I, Melms A, Trowsdale J. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs. J Exp Med 1996;184:2019-2024.
55. 55. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hämmerling GJ. Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J 1996;15:6144-6154.
56. 56. Fung-Leung WP, et al. Antigen presentation and T cell development in H2-M-deficient mice. Science 1996;271:1278-1281.
57. 57. Martin WD, Hicks GG, Mendiratta SK, Leva HI, Ruley HE, Van Kaer L. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Cell 1996;84:543-550.
58. 58. Miyazaki T, et al. Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell 1996;84:531-541.
59. 59. Kropshofer H, Hämmerling GJ, Vogt AB. How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? Immunol Today 1997;18:77-82.
60. 60. Katz JF, Stebbins C, Appella E, Sant AJ. Invariant chain and DM edit self-peptide presentation by Major Histocompatibility Complex (MHC) class II molecules. J Exp Med 1996;184:1747-1753.
61. 61. Lavoie PM, Thibodeau J, Cloutier I, Busch R, Sekaly RP. Selective binding of bacterial toxins to major histocompatibility complex class II-expressing cells is controlled by invariant chain and HLA-DM. Proc Natl Acad Sci USA 1997;94:6892-6897.
62. 62. Lightstone L, et al. In the absence of the invariant chain, HLA-DR molecules display a distinct array of peptides which is influenced by the presence or absence of HLA-DM. Proc Natl Acad Sci USA 1997;94:5772-5777.
63. 63. Tourne S, Miyazaki T, Wolf P, Ploegh H, Benoist C, Mathis D. Functionality of major histocompatibility complex class II molecules in mice doubly deficient for invariant chain and H-2M complexes. Proc Natl Acad Sci USA 1997;94:9255-9260.
64. 64. Swier K, Brown DR, Bird JJ, Martin WD, Van Kaer L, Reiner SL. A critical, invariant chain-independent role for H2-M in antigen presentation. J Immunol 1998;160:540-544.
65. 65. Kovats S, et al. Invariant chain-independent function of H-2M in the formation of endogenous peptide-major histocompatibility complex class II complexes in vivo. J Exp Med 1998;187:245-251.
66. 66. Rock KL, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761-771.
67. 67. Ciechanover A, Schwanz AL. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 1998;95:2727-2730.
68. 68. Nandi D, Marusina K, Monaco JJ. How do endogenous proteins become peptides and reach the endoplasmic reticulum. Curr Top Microbiol Immunol 1998;232:15-47.
69. 69. Monaco JJ. A molecular model of MHC class-I-restricted antigen processing. Immunol Today 1992;13:173-179.
70. 70. Neefjes JJ, Momburg F, Hämmerling GJ. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 1993;261:769-771.
71. 71. Shepherd JC, et al. TAP 1 -dependent peptide translocation in vitro is ATP dependent and peptide selective. Cell 1993;74:577-584.
72. 72. Powis SJ, Townsend AR, Deverson EV, Bastin J, Butcher GW, Howard JC. Restoration of antigen presentation to the mutant cell line RMA-S by an MHC-linked transporter. Nature 1991;354:528-531.
73. 73. Hughes EA, Hammond C, Cresswell P. Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. Proc Natl Acad Sci USA 1997;94:18960-18901.
74. 74. Wiertz EJ, et al. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 1996;384:432-438.
75. 75. Kovacsovics-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 1995;267:243-246.
76. 76. Pfeifer JD, Wick MJ, Roberts RL, Findlay K, Normark SJ, Harding CV. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 1993;361:359-362.
77. 77. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 1996;17:131-137.
78. 78. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999;398:77-80.
79. 79. Reis e Sousa C, Germain RN. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J Exp Med 1995;182:841-851.
80. 80. Harding CV, Song R. Phagocytic processing of exogenous paniculate antigens by macrophages for presentation by class I MHC molecules. J Immunol 1994;153:4925-4933.
81. 81. Olsen AC, et al. A quantitative assay to measure the interaction between immunogenic peptides and purified class I major histocompatibility complex molecules. Eur J Immunol 1994;24:385-392.
82. 82. Jensen PE, Moore JC, Lukacher AE. A europium fluoroimmunoassay for measuring peptide binding to MHC class I molecules. J Immunol Meth 1998;215:71-80.
83. 83. Reich Z, et al. Stability of empty and peptide-loaded class II major histocompatibility complex molecules at neutral and endosomal pH: comparison to class I proteins. Proc Natl Acad Sci USA 1997;94:2495-2500.
84. 84. Sijts AJ, Pamer EG. Enhanced intracellular dissociation of major histocompatibility complex class I associated peptides: a mechanism for optimizing the spectrum of cell surface-presented cytotoxic T lymphocyte epitopes. J Exp Med 1997;185:1403-1411.
85. 85. Ortmann B, et al. A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science 1997;277:1306-1309.
86. 86. Lehner PJ, Surman MJ, Cresswell P. Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line .220. Immunity 1998;8:221-231.
87. 87. Schoenhals GJ, et al. Retention of empty MHC class I molecules by tapasin is essential to reconstitute antigen presentation in invertebrate cells. EMBO J 1999;18:743-753.
88. h class I major histocompatibility complex binding of an exogenous influenza peptide. Proc Natl Acad Sci USA 1991;88:301-304.
89. 2-microglobulin in peptide bindiing by class I molecules. Science 1990;250:1423-1426.
90. 90. Fairchild PJ, Wraith DC. Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC. Immunol Today 1996;17:80-85.
91. 91. Fairchild PJ, Wildgoose R, Atherton E, Webb S, Wraith DC. An autoantigenic T cell epitope forms unstable complexes with class II MHC: a novel route for escape from tolerance induction. Int Immunol 1993;5:1151-1158.
92. 92. Joosten I, et al. Direct binding of autoimmune disease related T cell epitopes to purified Lewis rat MHC class II molecules. Int Immunol 1994;6:751-759.
93. 93. Carrasco-Marin E, Shimizu J, Kanagawa O, Unanue ER. The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders. J Immunol 1996;156:450-458.
94. 94. Harrington CJ, et al. Differential tolerance is induced in T cells recognizing distinct epitopes of myelin basic protein. Immunity 1998;8:571-580.
95. 95. Jensen PE. Antigen processing: HLA-DO -a hitchhiking inhibitor of HLA-DM. Curr Biol 1998;8:R128-R131.
96. 96. Karlsson L. Surh CD, Sprent J, Peterson PA. A novel class II MHC molecule with unusual tissue distribution. Nature 1991;351:485-488.
97. 97. Karlsson L, Peterson PA. The α chain gene of H-2O has an unexpected location in the major histocompatibility complex. J Exp Med 1992;176:477-483.
98. 98. Liljedahl M, Kuwana T, Fung-Leung WP, Jackson MR, Peterson PA, Karlsson L. HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J 1996;15:4817-4824.
99. 99. Denzin LK, Sant'Angelo DB, Hammond C, Surman MJ, Cresswell P. Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science 1997;278:106-109.
100. 100. Van Ham SM, et al. HLA-DO is a negative modulator of HLA-DM mediated MHC class II peptide loading. Curr Biol 1997;7:950-957.
101. 101. Liljedahl M, et al. Altered antigen presentation in mice lacking H2-O. Immunity 1998;8:233-243.
102. 102. Kropshofer H, et al. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J 1998;17:2971-2981.